Mario Tumbarello

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6950505/publications.pdf

Version: 2024-02-01

169 papers	11,268 citations	25034 57 h-index	32842 100 g-index
173 all docs	173 docs citations	173 times ranked	10124 citing authors

#	Article	IF	Citations
1	XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?. Antibiotics, 2022, 11, 193.	3.7	3
2	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	32.4	
3	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	4.0	13
4	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. JAC-Antimicrobial Resistance, 2022, 4, dlac022.	2.1	17
5	Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.5	11
6	New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics, 2022, 11, 579.	3.7	31
7	Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry. Journal of Chemotherapy, 2022, 34, 524-533.	1.5	3
8	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal of Antimicrobial Agents, 2022, 60, 106611.	2.5	36
9	Efficacy of Î²â€lactam/Î²â€lactamase inhibitors to treat extendedâ€spectrum betaâ€lactamaseâ€producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENTâ€SOT Project). Transplant Infectious Disease, 2021, 23, e13520.	1.7	10
10	Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. Critical Reviews in Oncology/Hematology, 2021, 158, 103203.	4.4	4
11	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemaseâ€“Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
12	Staphylococcus aureus ventilator-associated pneumonia in patients with COVID-19: clinical features and potential inference with lung dysbiosis. Critical Care, 2021, 25, 197.	5.8	41
13	A new call for influenza and pneumococcal vaccinations during COVID-19 pandemic in Italy: a SIP/IRS (Italian Respiratory Society) and SITA (Italian Society of Antiinfective therapy) statement. Respiratory Medicine, 2021, 190, 106674.	2.9	3
14	Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study. Antibiotics, 2021, 10, 1554.	3.7	1
15	Use of colistin in adult patients: A cross-sectional study. Journal of Global Antimicrobial Resistance, 2020, 20, 43-49.	2.2	29
16	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. American Journal of Transplantation, 2020, 20, 1629-1641.	4.7	17
17	Molecular Mechanisms, Epidemiology, and Clinical Importance of Î²-Lactam Resistance in Enterobacteriaceae. International Journal of Molecular Sciences, 2020, 21, 5090.	4.1	60
18	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Caseâ€“Control Study. Open Forum Infectious Diseases, 2020, 7, ofaa233.	0.9	7

#	Article	IF	Citations
19	(1,3)-Î²-d-Glucan-based empirical antifungal interruption in suspected invasive candidiasis: a randomized trial. Critical Care, 2020, 24, 550.	5.8	30
20	Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains. International Journal of Antimicrobial Agents, 2020, 55, 105900.	2.5	11
21	Meropenem/vaborbactam: a next generation Î²-lactam Î²-lactamase inhibitor combination. Expert Review of Anti-Infective Therapy, 2020, 18, 643-655.	4.4	64
22	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infectious Diseases, 2020, 7, ofaa139.	0.9	49
23	Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Annals of Intensive Care, 2020, 10, 94.	4.6	36
24	Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data. Infection and Drug Resistance, 2020, Volume 13, 4697-4711.	2.7	21
25	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused byKlebsiella pneumoniaeCarbapenemaseâ€“producingK. pneumoniae. Clinical Infectious Diseases, 2019, 68, 355-364.	5.8	265
26	Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey. PLoS ONE, 2019, 14, e0224465.	2.5	27
27	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	3.3	67
28	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	5.8	123
29	Direct use of eazyplex^{Â®} SuperBug CRE assay from positive blood cultures in conjunction with inpatient infectious disease consulting for timely appropriate antimicrobial therapy in Escherichia coli and Klebsiella pneumoniae bloodstream infections . Infection and Drug Resistance, 2019, Volume 12, 1055-1062.	2.7	11
30	Fungaemia in haematological malignancies: SEIFEMâ€2015 survey. European Journal of Clinical Investigation, 2019, 49, e13083.	3.4	20
31	The role of carbapenem-resistant pathogens in cSSTI and how to manage them. Current Opinion in Infectious Diseases, 2019, 32, 113-122.	3.1	11
32	Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients. Journal of Critical Care, 2019, 50, 169-176.	2.2	18
33	Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. International Journal of Antimicrobial Agents, 2019, 53, 408-415.	2.5	120
34	â€˜Real-lifeâ€™ analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. Journal of Antimicrobial Chemotherapy, 2019, 74, 1062-1068.	3.0	11
35	Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 413-417.	2.9	12
36	Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry. Journal of Chemotherapy, 2019, 31, 9-14.	1.5	14

#	Article	IF	Citations
37	Ceftolozane/tazobactam: place in therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 307-320.	4.4	100
38	Predictors of Mortality with Staphylococcus aureus Bacteremia in Elderly Adults. Journal of the American Geriatrics Society, 2018, 66, 1284-1289.	2.6	18
39	The current role of glycopeptides in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in not neutropenic adults: the viewpoint of a group of Italian experts. Journal of Chemotherapy, 2018, 30, 157-171.	1.5	0
40	Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). Annals of Hematology, 2018, 97, 791-798.	1.8	10
41	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	2.5	55
42	Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?. Intensive Care Medicine, 2018, 44, 1982-1984.	8.2	3
43	Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections. Current Opinion in Infectious Diseases, 2018, 31, 566-577.	3.1	40
44	T2Bacteria magnetic resonance assay for the rapid detection of ESKAPEc pathogens directly in whole blood. Journal of Antimicrobial Chemotherapy, 2018, 73, iv20-iv26.	3.0	64
45	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-Î²-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	3.0	46
46	Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence, 2017, 8, 470-484.	4.4	97
47	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
48	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
49	SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy. Leukemia and Lymphoma, 2017, 58, 2859-2864.	1.3	6
50	Prosthetic valve endocarditis: predictors of early outcome of surgical therapy. A multicentric study. European Journal of Cardio-thoracic Surgery, 2017, 52, 768-774.	1.4	29
51	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	1.6	34
52	Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update. Journal of Chemotherapy, 2017, 29, 197-214.	1.5	81
53	Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. Haematologica, 2017, 102, e407-e410.	3.5	17
54	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8

#	Article	IF	Citations
55	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. Surgical Infections, 2017, 18, 846-853.	1.4	31
56	Antibodies against a Î²-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. Scientific Reports, 2017, 7, 2722.	3.3	12
57	Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations. Blood Reviews, 2017, 31, 17-29.	5.7	98
58	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
59	Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials. Open Forum Infectious Diseases, 2017, 4, ofx063.	0.9	44
60	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardshipâ€”results from an international cross-sectional survey. World Journal of Emergency Surgery, 2017, 12, 34.	5.0	47
61	Combined use of serum (1,3)-Î²-d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Critical Care, 2017, 21, 176.	5.8	65
62	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. PLoS ONE, 2017, 12, e0170236.	2.5	67
63	(1,3)-Î²-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study. Journal of Antimicrobial Chemotherapy, 2016, 71, 2262-2269.	3.0	73
64	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
65	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
66	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. European Journal of Internal Medicine, 2016, 34, 45-53.	2.2	8
67	Bloodstream infections caused by Klebsiella pneumoniae in oncoâ€hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. American Journal of Hematology, 2016, 91, 1076-1081.	4.1	115
68	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. Critical Care, 2016, 20, 246.	5.8	9
69	Comment on: Mortality due tobla_{KPC}Klebsiella pneumoniaebacteraemia. Journal of Antimicrobial Chemotherapy, 2016, 71, 1743.1-1744.	3.0	6
70	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
71	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Final Results of a Multicentric Prospective Observational Seifem Study. Blood, 2016, 128, 3700-3700.	1.4	0
72	Multidrug-resistant bacteria and bloodstream infections in onco-hematological patients. Journal of Chemotherapy, 2015, 27, 250-252.	1.5	1

#	Article	IF	Citations
73	Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the <scp>SEIFEM</scp>â€Ð registry. British Journal of Haematology, 2015, 170, 434-439.	2.5	14
74	Fungal infections in the ICU. Current Opinion in Critical Care, 2015, 21, 421-429.	3.2	32
75	Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study). Haematologica, 2015, 100, 284-292.	3.5	64
76	Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Medicine, 2015, 41, 103-110.	8.2	37
77	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine, 2015, 41, 1601-1610.	8.2	165
78	Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	3.0	434
79	Antifungal Susceptibility Profiles of Bloodstream Yeast Isolates by Sensititre YeastOne over Nine Years at a Large Italian Teaching Hospital. Antimicrobial Agents and Chemotherapy, 2015, 59, 3944-3955.	3.2	68
80	Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Medicine, 2015, 41, 776-795.	8.2	133
81	Infections caused by KPC-producingKlebsiella pneumoniae: differences in therapy and mortality in a multicentre studyâ€"authors' response. Journal of Antimicrobial Chemotherapy, 2015, 70, 2922-2922.	3.0	60
82	Reply to Wong et al. Clinical Infectious Diseases, 2015, 61, 1352-1352.	5.8	1
83	Bloodstream Infections Caused By Klebsiella Pneumoniae in Onco-Hematological Patients: Incidence and Clinical Impact of Carbapenem Resistance in a Multicentre Prospective Survey. Blood, 2015, 126, 3757-3757.	1.4	3
84	Bloodstream Infections in Hematological Cancer Patients Colonized By Multiresistant Bacteria: Results of a Multicentric Prospective Observational Seifem Study. Blood, 2015, 126, 1023-1023.	1.4	0
85	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. Blood, 2015, 126, 4887-4887.	1.4	1
86	CarbapenemaseproducingKlebsiella pneumoniaeand Hematologic Malignancies. Emerging Infectious Diseases, 2014, 20, 1235-1236.	4.3	48
87	Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer. Current Opinion in Infectious Diseases, 2014, 27, 200-210.	3.1	125
88	Relapsing bloodstream infections during treatment of acute leukemia. Annals of Hematology, 2014, 93, 785-790.	1.8	19
89	Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy, 2014, 58, 851-858.	3.2	91
90	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	3.2	75

#	Article	IF	Citations
91	High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care, 2014, 18, R90.	5.8	192
92	Performance of Two Resin-Containing Blood Culture Media in Detection of Bloodstream Infections and in Direct Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry (MALDI-TOF MS) Broth Assays for Isolate Identification: Clinical Comparison of the BacT/Alert Plus and Bactec Plus Systems. Journal of Clinical Microbiology, 2014, 52, 3558-3567.	3.9	48
93	Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey. Journal of Antimicrobial Chemotherapy, 2014, 69, 3142-3147.	3.0	21
94	A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Medicine, 2014, 40, 839-845.	8.2	209
95	Response. Chest, 2014, 145, 927-928.	0.8	0
96	Carbapenem-Resistant Enterobacteriaceae (CRE) and Their Impact on Stem Cell Transplantation: A Single Center Experience. Blood, 2014, 124, 3880-3880.	1.4	9
97	Invasive Fungal Infections in Acute Promyelocytic Leukemia Patients. Results of a Prospective Multicenter Study in Italy. Blood, 2014, 124, 3682-3682.	1.4	0
98	Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain. Journal of Clinical Microbiology, 2013, 51, 4167-4172.	3.9	176
99	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine, 2013, 39, 2092-2106.	8.2	169
100	Predictors of mortality in multidrug-resistantKlebsiella pneumoniaebloodstream infections. Expert Review of Anti-Infective Therapy, 2013, 11, 1053-1063.	4.4	82
101	Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Medicine, 2013, 39, 682-692.	8.2	137
102	Effect of Aerosolized Colistin as Adjunctive Treatment on the Outcomes of Microbiologically Documented Ventilator-Associated Pneumonia Caused by Colistin-Only Susceptible Gram-Negative Bacteria. Chest, 2013, 144, 1768-1775.	0.8	150
103	Mortality in patients with early- or late-onset candidaemia. Journal of Antimicrobial Chemotherapy, 2013, 68, 927-935.	3.0	37
104	Why Should We Monitor (1-3)-Î²- <scp>d</scp> -Glucan Levels during Invasive Candidiasis? Just Ask Your Ophthalmologist!. Journal of Clinical Microbiology, 2013, 51, 1645-1646.	3.9	7
105	Reply to â€œIdentifying Patients Harboring Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae on Hospital Admission Is Not That Simpleâ€• Antimicrobial Agents and Chemotherapy, 2012, 56, 2220-2220.	3.2	1
106	Severe pneumonia in intensive care. Current Opinion in Pulmonary Medicine, 2012, 18, 213-221.	2.6	34
107	High-Dose Daptomycin for Cardiac Implantable Electronic Device-Related Infective Endocarditis Caused by Staphylococcal Small-Colony Variants. Clinical Infectious Diseases, 2012, 54, 1516-1517.	5.8	12
108	Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy. Clinical Infectious Diseases, 2012, 55, 943-950.	5.8	855

#	Article	IF	Citations
109	Safety and Effectiveness of Transvenous Lead Extraction in Octogenarians. Journal of Cardiovascular Electrophysiology, 2012, 23, 1103-1108.	1.7	25
110	Neurological involvement during legionellosis, look beyond the lung. Journal of Neurology, 2012, 259, 2243-2245.	3.6	3
111	Direct MALDI-TOF Mass Spectrometry Assay of Blood Culture Broths for Rapid Identification of Candida Species Causing Bloodstream Infections: an Observational Study in Two Large Microbiology Laboratories. Journal of Clinical Microbiology, 2012, 50, 176-179.	3.9	190
112	Detecting risk and predicting patient mortality in patients with extended-spectrum Î²-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiology, 2012, 7, 1173-1189.	2.0	55
113	Multidrug-Resistant Proteus mirabilis Bloodstream Infections: Risk Factors and Outcomes. Antimicrobial Agents and Chemotherapy, 2012, 56, 3224-3231.	3.2	51
114	Evaluation of the Practice of Antifungal Prophylaxis Use in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results From the SEIFEM 2010-B Registry. Clinical Infectious Diseases, 2012, 55, 1515-1521.	5.8	77
115	Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital. PLoS ONE, 2012, 7, e33705.	2.5	170
116	Evaluation of the New NucliSENS EasyQ KPC Test for Rapid Detection of Klebsiella pneumoniae Carbapenemase Genes (bla _{KPC}). Journal of Clinical Microbiology, 2012, 50, 2783-2785.	3.9	38
117	Derivation and Validation of a Scoring System to Identify Patients with Bacteremia and Hematological Malignancies at Higher Risk for Mortality. PLoS ONE, 2012, 7, e51612.	2.5	18
118	Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1â†'3)-Î²-D-glucan assay, Candida score, and colonization index. Critical Care, 2011, 15, R249.	5.8	152
119	Uncommon yeast infections in hematological patients: from diagnosis to treatment. Expert Review of Anti-Infective Therapy, 2011, 9, 1067-1075.	4.4	18
120	The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica, 2011, 96, 1366-1370.	3.5	56
121	Esthesioneuroblastoma in an HIV-1 Infected Patient: Case Report. Skull Base Reports, 2011, 1, 129-132.	0.0	0
122	Etiology of Febrile Episodes in Patients With Acute Myeloid Leukemia: Results From the Hema e-Chart Registry. Archives of Internal Medicine, 2011, 171, 1502.	3.8	27
123	Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica, 2011, 96, e1-e3.	3.5	67
124	Identifying Patients Harboring Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System. Antimicrobial Agents and Chemotherapy, 2011, 55, 3485-3490.	3.2	137
125	In Vitro Activities of Anidulafungin and Other Antifungal Agents against Biofilms Formed by Clinical Isolates of Different Candida and Aspergillus Species. Antimicrobial Agents and Chemotherapy, 2011, 55, 3031-3035.	3.2	67
126	Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum-Î²-Lactamase Production and Inadequate Initial Antibiotic Therapy. Antimicrobial Agents and Chemotherapy, 2010, 54, 4085-4091.	3.2	185

#	Article	IF	Citations
127	Fluconazole Use as an Important Risk Factor in the Emergence of Fluconazole-Resistant Candida glabrata Fungemia. Archives of Internal Medicine, 2009, 169, 1444.	3.8	5
128	Incidence and clinical impact of extended-spectrum-Î²-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. Journal of Infection, 2009, 58, 299-307.	3.3	144
129	Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagnostic Microbiology and Infectious Disease, 2009, 64, 320-326.	1.8	82
130	Oral lesions in HIV and HCV coâ€infected individuals in HAART era. Journal of Oral Pathology and Medicine, 2008, 37, 468-474.	2.7	10
131	Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase- Producing Escherichia coli : Risk Factors for Inadequate Initial Antimicrobial Therapy. Antimicrobial Agents and Chemotherapy, 2008, 52, 3244-3252.	3.2	104
132	Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. Journal of Antimicrobial Chemotherapy, 2008, 62, 1379-1385.	3.0	50
133	Oral Lichenoid Lesions in HIV-HCV-Coinfected Subjects During Antiviral Therapy: 2 Cases and Review of the Literature. American Journal of Dermatopathology, 2008, 30, 466-471.	0.6	18
134	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2007, 51, 1987-1994.	3.2	382
135	Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. Journal of Clinical Microbiology, 2007, 45, 1843-1850.	3.9	300
136	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial Treatment. Antimicrobial Agents and Chemotherapy, 2007, 51, 3469-3469.	3.2	5
137	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagnostic Microbiology and Infectious Disease, 2007, 58, 325-331.	1.8	104
138	Candidainfections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Review of Anti-Infective Therapy, 2006, 4, 875-885.	4.4	22
139	Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Research and Therapy, 2006, 3, 22.	1.7	33
140	Bloodstream Infections Caused by Extended-Spectrum-Î²-Lactamase-Producing Klebsiella pneumoniae : Risk Factors, Molecular Epidemiology, and Clinical Outcome. Antimicrobial Agents and Chemotherapy, 2006, 50, 498-504.	3.2	243
141	Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates. Journal of Clinical Microbiology, 2006, 44, 3257-3262.	3.9	57
142	Azole Resistance of Candida glabrata in a Case of Recurrent Fungemia. Journal of Clinical Microbiology, 2006, 44, 3046-3047.	3.9	27
143	ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. Journal of Antimicrobial Chemotherapy, 2004, 53, 277-282.	3.0	68
144	Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy. BMC Infectious Diseases, 2004, 4, 46.	2.9	65

#	Article	IF	Citations
145	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. Aids, 2004, 18, 1602-1604.	2.2	2
146	Older HIV-positive patients in the era of highly active antiretroviral therapy. Aids, 2003, 17, 128-131.	2.2	55
147	Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. Aids, 2003, 17, 765-768.	2.2	54
148	Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitutionâ€“Independent Beneficial Effect onCandidaVirulence and Oral Candidiasis in Human Immunodeficiency Virusâ€“Infected Subjects. Journal of Infectious Diseases, 2002, 185, 188-195.	4.0	79
149	Azole Susceptibility Patterns and Genetic Relationship Among Oral Candida Strains Isolated in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 38-44.	2.1	17
150	Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2002, 50, 375-382.	3.0	66
151	Multidrug-Resistant Pseudomonas Aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology. Emerging Infectious Diseases, 2002, 8, 220-221.	4.3	75
152	Glycopeptide Resistance among Coagulaseâ€Negative Staphylococci that Cause Bacteremia: Epidemiological and Clinical Findings from a Caseâ€Control Study. Clinical Infectious Diseases, 2001, 33, 1628-1635.	5.8	48
153	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 145-151.	2.1	15
154	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 145-151.	2.1	54
155	Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. Aids, 2000, 14, 2948-2949.	2.2	20
156	Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 20-25.	2.1	126
157	In Vitro and In Vivo Anticandidal Activity of Human Immunodeficiency Virus Protease Inhibitors. Journal of Infectious Diseases, 1999, 180, 448-453.	4.0	205
158	HIV-Associated Bacterial Pneumonia in the Era of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes, 1999, 20, 208-209.	0.3	20
159	Highly Active Antiretroviral Therapy Decreases the Incidence of Bacteremia in Human Immunodeficiency Virusâ€Infected Individuals. Clinical Infectious Diseases, 1998, 27, 901-902.	5.8	21
160	Nosocomial Bloodstream Infections in HIV-Infected Patients: Attributable Mortality and Extension of Hospital Stay. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 490-497.	0.3	32
161	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. European Journal of Gastroenterology and Hepatology, 1997, 9, 307-310.	1.6	26
162	Osteoarticular bacterial infections are rare in HIV-infected patients: 14 cases found among 4, 023 HIV-infected patients. Acta Orthopaedica, 1997, 68, 554-558.	1.4	35

#	Article	IF	Citations
163	Age as a prognostic factor in AIDS. Lancet, The, 1996, 348, 623-624.	13.7	9
164	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. Journal of Antimicrobial Chemotherapy, 1996, 38, 691-699.	3.0	55
165	P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. Immunology Letters, 1995, 47, 223-226.	2.5	7
166	Primary central nervous system lymphoma and brain biopsy in AIDS. Lancet, The, 1993, 341, 1411-1412.	13.7	15
167	Synthetic Peptides Corresponding to Sequences in HIV Envelope gp41 and gp120 EnhanceIn VitroProduction of Interleukin-1 and Tumor Necrosis Factor but Depress Production of Interferon-Î±, Interferon-Î³ and Interleukin-2. Viral Immunology, 1991, 4, 33-42.	1.3	41
168	A national voice for information about HIV infections: The Italian state AIDS hot-line. Public Health, 1989, 103, 447-454.	2.9	0
169	Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cellular Immunology, 1988, 115, 57-65.	3.0	52